{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:11:20Z","timestamp":1786446680363,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81272182"],"award-info":[{"award-number":["No.81272182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Hunan Provincial Education Department","award":["16K077"],"award-info":[{"award-number":["16K077"]}]},{"name":"Innovation Platform Open Fund Project of Department of Education of Hunan Province","award":["20K110"],"award-info":[{"award-number":["20K110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00705-024-06095-3","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T17:02:01Z","timestamp":1721235721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["GB and gH\/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection"],"prefix":"10.1007","volume":"169","author":[{"given":"Changqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muchuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5575-5094","authenticated-orcid":false,"given":"Yunlian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"7335","key":"6095_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1(7335):702\u2013703","journal-title":"Lancet"},{"key":"6095_CR2","doi-asserted-by":"publisher","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui X, Snapper CM (2021) Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol 12:734471","journal-title":"Front Immunol"},{"issue":"1","key":"6095_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","volume":"148","author":"Y Wong","year":"2022","unstructured":"Wong Y et al (2022) Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol 148(1):31\u201346","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"6095_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00292-022-01081-5","volume":"43","author":"M Overkamp","year":"2022","unstructured":"Overkamp M, Quintanilla-Martinez L, Fend F (2022) EBV-associated lymphoproliferative disorders. Pathologie (Heidelb) 43(4):282\u2013291","journal-title":"Pathologie (Heidelb)"},{"issue":"20","key":"6095_CR5","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N (2022) Epstein-Barr virus: Biology and clinical disease. Cell 185(20):3652\u20133670","journal-title":"Cell"},{"key":"6095_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ (2019) Epstein-Barr Virus and Cancer. Annu Rev Pathol 14:29\u201353","journal-title":"Annu Rev Pathol"},{"issue":"70","key":"6095_CR7","doi-asserted-by":"publisher","first-page":"eabo7799","DOI":"10.1126\/sciimmunol.abo7799","volume":"7","author":"LM Sollid","year":"2022","unstructured":"Sollid LM (2022) Epstein-Barr virus as a driver of multiple sclerosis. Sci Immunol 7(70):eabo7799","journal-title":"Sci Immunol"},{"key":"6095_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijid.2020.12.051","volume":"104","author":"S Paolucci","year":"2021","unstructured":"Paolucci S et al (2021) EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis 104:315\u2013319","journal-title":"Int J Infect Dis"},{"key":"6095_CR9","doi-asserted-by":"crossref","first-page":"232470962110406","DOI":"10.1177\/23247096211040626","volume":"9","author":"A Nadeem","year":"2021","unstructured":"Nadeem A et al (2021) Epstein-Barr Virus Coinfection in COVID-19. J Investig Med High Impact Case Rep 9:23247096211040626","journal-title":"J Investig Med High Impact Case Rep"},{"key":"6095_CR10","doi-asserted-by":"crossref","unstructured":"Gold JE et al (2021) Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens, 10(6)","DOI":"10.3390\/pathogens10060763"},{"issue":"Pt 2","key":"6095_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2818.1989.tb00554.x","volume":"153","author":"FS Fay","year":"1989","unstructured":"Fay FS, Carrington W, Fogarty KE (1989) Three-dimensional molecular distribution in single cells analysed using the digital imaging microscope. J Microsc 153(Pt 2):133\u2013149","journal-title":"J Microsc"},{"issue":"5","key":"6095_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00430-018-0570-1","volume":"208","author":"H Yin","year":"2019","unstructured":"Yin H et al (2019) Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol 208(5):573\u2013583","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"6095_CR13","first-page":"476","volume":"30","author":"LL Zuo","year":"2014","unstructured":"Zuo LL et al (2014) [The entry of Epstein-Barr virus into B lymphocytes and epithelial cells during infection]. Bing Du Xue Bao 30(4):476\u2013482","journal-title":"Bing Du Xue Bao"},{"issue":"2","key":"6095_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","volume":"3","author":"JG Ogembo","year":"2013","unstructured":"Ogembo JG et al (2013) Human complement receptor type 1\/CD35 is an Epstein-Barr Virus receptor. Cell Rep 3(2):371\u2013385","journal-title":"Cell Rep"},{"issue":"4","key":"6095_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14348\/molcells.2016.0066","volume":"39","author":"BS Mohl","year":"2016","unstructured":"Mohl BS et al (2016) Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Mol Cells 39(4):286\u2013291","journal-title":"Mol Cells"},{"issue":"12","key":"6095_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young LS, Yap LF, Murray PG (2016) Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16(12):789\u2013802","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"6095_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu W et al (2019) Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. Immunity 50(5):1305\u20131316e6","journal-title":"Immunity"},{"issue":"3","key":"6095_CR18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1128\/JVI.73.3.2115-2125.1999","volume":"73","author":"JD Fingeroth","year":"1999","unstructured":"Fingeroth JD et al (1999) CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. J Virol 73(3):2115\u20132125","journal-title":"J Virol"},{"issue":"11","key":"6095_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C Munz","year":"2019","unstructured":"Munz C (2019) Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol 17(11):691\u2013700","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"6095_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.7150\/jca.37282","volume":"11","author":"R Ayee","year":"2020","unstructured":"Ayee R et al (2020) Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans. J Cancer 11(7):1737\u20131750","journal-title":"J Cancer"},{"issue":"4","key":"6095_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1620\/tjem.227.307","volume":"227","author":"Y Sakamoto","year":"2012","unstructured":"Sakamoto Y, Mariya Y, Kubo K (2012) Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection. Tohoku J Exp Med 227(4):307\u2013311","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"6095_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/v4091537","volume":"4","author":"L Frappier","year":"2012","unstructured":"Frappier L (2012) Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses 4(9):1537\u20131547","journal-title":"Viruses"},{"key":"6095_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.canlet.2017.10.016","volume":"431","author":"L Xu","year":"2018","unstructured":"Xu L et al (2018) The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett 431:230\u2013243","journal-title":"Cancer Lett"},{"issue":"14","key":"6095_CR24","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-11-3919","volume":"72","author":"A Kaneda","year":"2012","unstructured":"Kaneda A et al (2012) Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 72(14):3445\u20133450","journal-title":"Cancer Res"},{"issue":"19","key":"6095_CR25","doi-asserted-by":"publisher","first-page":"10179","DOI":"10.1128\/JVI.77.19.10179-10185.2003","volume":"77","author":"PG Spear","year":"2003","unstructured":"Spear PG, Longnecker R (2003) Herpesvirus entry: an update. J Virol 77(19):10179\u201310185","journal-title":"J Virol"},{"issue":"1","key":"6095_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.virol.2007.06.031","volume":"368","author":"M Backovic","year":"2007","unstructured":"Backovic M et al (2007) Characterization of EBV gB indicates properties of both class I and class II viral fusion proteins. Virology 368(1):102\u2013113","journal-title":"Virology"},{"issue":"2","key":"6095_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","volume":"19","author":"SA Connolly","year":"2021","unstructured":"Connolly SA, Jardetzky TS, Longnecker R (2021) The structural basis of herpesvirus entry. Nat Rev Microbiol 19(2):110\u2013121","journal-title":"Nat Rev Microbiol"},{"issue":"Pt 3","key":"6095_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1099\/vir.0.007237-0","volume":"90","author":"J Sorem","year":"2009","unstructured":"Sorem J, Longnecker R (2009) Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells. J Gen Virol 90(Pt 3):591\u2013595","journal-title":"J Gen Virol"},{"issue":"8","key":"6095_CR29","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1073\/pnas.0810530106","volume":"106","author":"M Backovic","year":"2009","unstructured":"Backovic M, Longnecker R, Jardetzky TS (2009) Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A 106(8):2880\u20132885","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6095_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-cellbio-101512-122422","volume":"30","author":"B Podbilewicz","year":"2014","unstructured":"Podbilewicz B (2014) Virus and cell fusion mechanisms. Annu Rev Cell Dev Biol 30:111\u2013139","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"6095_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1146\/annurev-virology-022221-063725","volume":"8","author":"HY Liu","year":"2021","unstructured":"Liu HY, Yang PL (2021) Small-Molecule Inhibition of Viral Fusion Glycoproteins. Annu Rev Virol 8(1):459\u2013489","journal-title":"Annu Rev Virol"},{"issue":"1","key":"6095_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.virol.2005.09.036","volume":"344","author":"M Kielian","year":"2006","unstructured":"Kielian M (2006) Class II virus membrane fusion proteins. Virology 344(1):38\u201347","journal-title":"Virology"},{"key":"6095_CR33","doi-asserted-by":"crossref","unstructured":"Guardado-Calvo P, Rey FA (2021) The Viral Class II Membrane Fusion Machinery: Divergent Evolution from an Ancestral Heterodimer. Viruses, 13(12)","DOI":"10.3390\/v13122368"},{"issue":"Pt 5","key":"6095_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1042\/BST0320707","volume":"32","author":"MA Lemmon","year":"2004","unstructured":"Lemmon MA (2004) Pleckstrin homology domains: not just for phosphoinositides. Biochem Soc Trans 32(Pt 5):707\u2013711","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"6095_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.sbi.2009.02.012","volume":"19","author":"M Backovic","year":"2009","unstructured":"Backovic M, Jardetzky TS (2009) Class III viral membrane fusion proteins. Curr Opin Struct Biol 19(2):189\u2013196","journal-title":"Curr Opin Struct Biol"},{"issue":"15","key":"6095_CR36","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1073\/pnas.1523234113","volume":"113","author":"T Zeev-Ben-Mordehai","year":"2016","unstructured":"Zeev-Ben-Mordehai T et al (2016) Two distinct trimeric conformations of natively membrane-anchored full-length herpes simplex virus 1 glycoprotein B. Proc Natl Acad Sci U S A 113(15):4176\u20134181","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6095_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virol.2010.12.006","volume":"413","author":"AE Plate","year":"2011","unstructured":"Plate AE et al (2011) Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH\/gL. Virology 413(1):26\u201338","journal-title":"Virology"},{"issue":"17","key":"6095_CR38","doi-asserted-by":"publisher","first-page":"9596","DOI":"10.1128\/JVI.00758-07","volume":"81","author":"M Backovic","year":"2007","unstructured":"Backovic M, Jardetzky TS, Longnecker R (2007) Hydrophobic residues that form putative fusion loops of Epstein-Barr virus glycoprotein B are critical for fusion activity. J Virol 81(17):9596\u20139600","journal-title":"J Virol"},{"issue":"13","key":"6095_CR39","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1128\/JVI.00301-09","volume":"83","author":"BP Hannah","year":"2009","unstructured":"Hannah BP et al (2009) Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol 83(13):6825\u20136836","journal-title":"J Virol"},{"key":"6095_CR40","doi-asserted-by":"crossref","unstructured":"Chen H et al (2021) T cell epitope screening of Epstein-Barr virus fusion protein gB. J Virol, 95(10)","DOI":"10.1128\/JVI.00081-21"},{"issue":"19","key":"6095_CR41","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1128\/JVI.00572-06","volume":"80","author":"AN Kirschner","year":"2006","unstructured":"Kirschner AN et al (2006) Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J Virol 80(19):9444\u20139454","journal-title":"J Virol"},{"key":"6095_CR42","doi-asserted-by":"crossref","unstructured":"Pino G-D, G.L. and, Heldwein EE (2022) Well Put Together-A Guide to Accessorizing with the Herpesvirus gH\/gL Complexes. Viruses, 14(2)","DOI":"10.3390\/v14020296"},{"key":"6095_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","volume":"18","author":"EE Heldwein","year":"2016","unstructured":"Heldwein EE (2016) gH\/gL supercomplexes at early stages of herpesvirus entry. Curr Opin Virol 18:1\u20138","journal-title":"Curr Opin Virol"},{"issue":"52","key":"6095_CR44","doi-asserted-by":"publisher","first-page":"22641","DOI":"10.1073\/pnas.1011806108","volume":"107","author":"H Matsuura","year":"2010","unstructured":"Matsuura H et al (2010) Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H\/glycoprotein L (gH\/gL) complex. Proc Natl Acad Sci U S A 107(52):22641\u201322646","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"6095_CR45","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1128\/JVI.00457-09","volume":"83","author":"AE Plate","year":"2009","unstructured":"Plate AE et al (2009) Functional analysis of glycoprotein L (gL) from rhesus lymphocryptovirus in Epstein-Barr virus-mediated cell fusion indicates a direct role of gL in gB-induced membrane fusion. J Virol 83(15):7678\u20137689","journal-title":"J Virol"},{"issue":"1","key":"6095_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.virol.2012.10.039","volume":"436","author":"CL Rowe","year":"2013","unstructured":"Rowe CL et al (2013) A soluble form of Epstein-Barr virus gH\/gL inhibits EBV-induced membrane fusion and does not function in fusion. Virology 436(1):118\u2013126","journal-title":"Virology"},{"issue":"1","key":"6095_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.coviro.2012.10.005","volume":"3","author":"SD Stampfer","year":"2013","unstructured":"Stampfer SD, Heldwein EE (2013) Stuck in the middle: structural insights into the role of the gH\/gL heterodimer in herpesvirus entry. Curr Opin Virol 3(1):13\u201319","journal-title":"Curr Opin Virol"},{"key":"6095_CR48","doi-asserted-by":"crossref","unstructured":"Chen J et al (2012) The KGD motif of Epstein-Barr virus gH\/gL is bifunctional, orchestrating infection of B cells and epithelial cells. mBio, 3(1)","DOI":"10.1128\/mBio.00290-11"},{"issue":"2","key":"6095_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","volume":"3","author":"H Zhang","year":"2018","unstructured":"Zhang H et al (2018) Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Nat Microbiol 3(2):1\u20138","journal-title":"Nat Microbiol"},{"key":"6095_CR50","doi-asserted-by":"crossref","unstructured":"Mohl BS et al (2017) Epstein-Barr Virus Fusion with Epithelial Cells Triggered by gB Is Restricted by a gL Glycosylation Site. J Virol, 91(23)","DOI":"10.1128\/JVI.01255-17"},{"issue":"4","key":"6095_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","volume":"56","author":"MA Epstein","year":"1976","unstructured":"Epstein MA (1976) Epstein-Barr virus\u2013is it time to develop a vaccine program? J Natl Cancer Inst 56(4):697\u2013700","journal-title":"J Natl Cancer Inst"},{"key":"6095_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fonc.2019.00104","volume":"9","author":"DG van Zyl","year":"2019","unstructured":"van Zyl DG, Mautner J, Delecluse HJ (2019) Progress in EBV Vaccines. Front Oncol 9:104","journal-title":"Front Oncol"},{"key":"6095_CR53","doi-asserted-by":"crossref","unstructured":"Cai J et al (2021) Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction. Vaccines (Basel), 9(11)","DOI":"10.3390\/vaccines9111290"},{"issue":"4","key":"6095_CR54","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","volume":"112","author":"C Gurer","year":"2008","unstructured":"Gurer C et al (2008) Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112(4):1231\u20131239","journal-title":"Blood"},{"issue":"4","key":"6095_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10822-016-9899-y","volume":"30","author":"E Gianti","year":"2016","unstructured":"Gianti E et al (2016) Computational analysis of EBNA1 druggability suggests novel insights for Epstein-Barr virus inhibitor design. J Comput Aided Mol Des 30(4):285\u2013303","journal-title":"J Comput Aided Mol Des"},{"issue":"3","key":"6095_CR56","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1535-7163.MCT-11-0725","volume":"11","author":"R Chen","year":"2012","unstructured":"Chen R et al (2012) A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther 11(3):594\u2013603","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"6095_CR57","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","volume":"64","author":"Y Si","year":"2016","unstructured":"Si Y et al (2016) The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up. Chem Pharm Bull (Tokyo) 64(8):1118\u20131123","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"3","key":"6095_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11427-011-4147-0","volume":"54","author":"Z Wang","year":"2011","unstructured":"Wang Z et al (2011) Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination. Sci China Life Sci 54(3):263\u2013266","journal-title":"Sci China Life Sci"},{"key":"6095_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2019.07.026","volume":"536","author":"LZ Mutsvunguma","year":"2019","unstructured":"Mutsvunguma LZ et al (2019) Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Virology 536:1\u201315","journal-title":"Virology"},{"issue":"4","key":"6095_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#","volume":"55","author":"C Cox","year":"1998","unstructured":"Cox C et al (1998) Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge. J Med Virol 55(4):255\u2013261","journal-title":"J Med Virol"},{"key":"6095_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","volume":"13","author":"JG Ogembo","year":"2015","unstructured":"Ogembo JG et al (2015) A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 13:50","journal-title":"J Transl Med"},{"issue":"5","key":"6095_CR62","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M et al (2015) Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 162(5):1090\u20131100","journal-title":"Cell"},{"key":"6095_CR63","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fimmu.2018.00932","volume":"9","author":"B Zhao","year":"2018","unstructured":"Zhao B et al (2018) Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB\/c Mice Model. Front Immunol 9:932","journal-title":"Front Immunol"},{"issue":"12","key":"6095_CR64","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM et al (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"13","key":"6095_CR65","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/0264-410X(94)90240-2","volume":"12","author":"S Finerty","year":"1994","unstructured":"Finerty S et al (1994) Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12(13):1180\u20131184","journal-title":"Vaccine"},{"issue":"7\u20138","key":"6095_CR66","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","volume":"17","author":"WT Jackman","year":"1999","unstructured":"Jackman WT et al (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17(7\u20138):660\u2013668","journal-title":"Vaccine"},{"issue":"23","key":"6095_CR67","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.vaccine.2016.04.012","volume":"34","author":"DS Heeke","year":"2016","unstructured":"Heeke DS et al (2016) Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits. Vaccine 34(23):2562\u20132569","journal-title":"Vaccine"},{"issue":"1","key":"6095_CR68","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","volume":"14","author":"V Dasari","year":"2023","unstructured":"Dasari V et al (2023) Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nat Commun 14(1):4371","journal-title":"Nat Commun"},{"issue":"30","key":"6095_CR69","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X et al (2013) A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine 31(30):3039\u20133045","journal-title":"Vaccine"},{"issue":"6","key":"6095_CR70","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1021\/acs.nanolett.0c04687","volume":"21","author":"YF Kang","year":"2021","unstructured":"Kang YF et al (2021) Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection. Nano Lett 21(6):2476\u20132486","journal-title":"Nano Lett"},{"key":"6095_CR71","doi-asserted-by":"publisher","first-page":"867918","DOI":"10.3389\/fimmu.2022.867918","volume":"13","author":"GM Escalante","year":"2022","unstructured":"Escalante GM et al (2022) Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective. Front Immunol 13:867918","journal-title":"Front Immunol"},{"issue":"5","key":"6095_CR72","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker LM, Burton DR (2018) Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol 18(5):297\u2013308","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"6095_CR73","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1128\/jvi.62.4.1108-1114.1988","volume":"62","author":"DE Oba","year":"1988","unstructured":"Oba DE, Hutt-Fletcher LM (1988) Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame. J Virol 62(4):1108\u20131114","journal-title":"J Virol"},{"issue":"7","key":"6095_CR74","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1128\/jvi.69.7.3987-3994.1995","volume":"69","author":"Q Li","year":"1995","unstructured":"Li Q, Turk SM, Hutt-Fletcher LM (1995) The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol 69(7):3987\u20133994","journal-title":"J Virol"},{"key":"6095_CR75","doi-asserted-by":"publisher","first-page":"13557","DOI":"10.1038\/ncomms13557","volume":"7","author":"K Sathiyamoorthy","year":"2016","unstructured":"Sathiyamoorthy K et al (2016) Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. Nat Commun 7:13557","journal-title":"Nat Commun"},{"issue":"24","key":"6095_CR76","doi-asserted-by":"publisher","first-page":"13214","DOI":"10.1128\/JVI.05580-11","volume":"85","author":"LS Chesnokova","year":"2011","unstructured":"Chesnokova LS, Hutt-Fletcher LM (2011) Fusion of Epstein-Barr virus with epithelial cells can be triggered by alphavbeta5 in addition to alphavbeta6 and alphavbeta8, and integrin binding triggers a conformational change in glycoproteins gHgL. J Virol 85(24):13214\u201313223","journal-title":"J Virol"},{"issue":"41","key":"6095_CR77","doi-asserted-by":"publisher","first-page":"E8703","DOI":"10.1073\/pnas.1704661114","volume":"114","author":"K Sathiyamoorthy","year":"2017","unstructured":"Sathiyamoorthy K et al (2017) Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. Proc Natl Acad Sci U S A 114(41):E8703\u2013E8710","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6095_CR78","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","volume":"48","author":"J Snijder","year":"2018","unstructured":"Snijder J et al (2018) An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. Immunity 48(4):799\u2013811e9","journal-title":"Immunity"},{"issue":"1","key":"6095_CR79","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1038\/s41467-021-26912-6","volume":"12","author":"QY Zhu","year":"2021","unstructured":"Zhu QY et al (2021) A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nat Commun 12(1):6624","journal-title":"Nat Commun"},{"issue":"8","key":"6095_CR80","doi-asserted-by":"publisher","first-page":"e0007522","DOI":"10.1128\/jvi.00075-22","volume":"96","author":"J Hong","year":"2022","unstructured":"Hong J et al (2022) A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge In Vivo. J Virol 96(8):e0007522","journal-title":"J Virol"},{"key":"6095_CR81","doi-asserted-by":"publisher","first-page":"920467","DOI":"10.3389\/fimmu.2022.920467","volume":"13","author":"J Hong","year":"2022","unstructured":"Hong J et al (2022) Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells. Front Immunol 13:920467","journal-title":"Front Immunol"},{"issue":"32","key":"6095_CR82","doi-asserted-by":"publisher","first-page":"e2202371119","DOI":"10.1073\/pnas.2202371119","volume":"119","author":"X Zhang","year":"2022","unstructured":"Zhang X et al (2022) Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proc Natl Acad Sci U S A 119(32):e2202371119","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6095_CR83","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055\u20131065","journal-title":"Clin Vaccine Immunol"},{"issue":"643","key":"6095_CR84","doi-asserted-by":"publisher","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"CJ Wei","year":"2022","unstructured":"Wei CJ et al (2022) A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci Transl Med 14(643):eabf3685","journal-title":"Sci Transl Med"},{"issue":"34","key":"6095_CR85","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui X et al (2016) Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34(34):4050\u20134055","journal-title":"Vaccine"},{"key":"6095_CR86","doi-asserted-by":"crossref","unstructured":"Cui X et al (2021) Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge. Vaccines (Basel), 9(3)","DOI":"10.3390\/vaccines9030285"},{"issue":"7","key":"6095_CR87","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ (2017) Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther 25(7):1467\u20131475","journal-title":"Mol Ther"},{"issue":"11","key":"6095_CR88","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun C et al (2023) A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 31(11):1882\u20131897e10","journal-title":"Cell Host Microbe"},{"issue":"9","key":"6095_CR89","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","volume":"11","author":"R Noad","year":"2003","unstructured":"Noad R, Roy P (2003) Virus-like particles as immunogens. Trends Microbiol 11(9):438\u2013444","journal-title":"Trends Microbiol"},{"issue":"12","key":"6095_CR90","doi-asserted-by":"publisher","first-page":"19255","DOI":"10.18632\/oncotarget.13770","volume":"8","author":"EM Perez","year":"2017","unstructured":"Perez EM et al (2017) Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice. Oncotarget 8(12):19255\u201319273","journal-title":"Oncotarget"},{"key":"6095_CR91","doi-asserted-by":"crossref","unstructured":"Escalante GM et al (2020) A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits. Vaccines (Basel), 8(2)","DOI":"10.3390\/vaccines8020169"},{"issue":"2","key":"6095_CR92","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni G, Mantovani A (2021) Covid-19 Commission of Accademia Nazionale dei Lincei, COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28(2):626\u2013639","journal-title":"Cell Death Differ"},{"issue":"1","key":"6095_CR93","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC et al (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6(1):28","journal-title":"NPJ Vaccines"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06095-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-024-06095-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06095-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T16:04:31Z","timestamp":1724083471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-024-06095-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["6095"],"URL":"https:\/\/doi.org\/10.1007\/s00705-024-06095-3","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"167"}}